Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more
ENTX is expected to report earnings to rise 16.67% to -7 cents per share on May 09
Q1'25
Est.
$-0.07
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.03
Q2'24
Est.
$-0.06
Q1'24
Beat
by $0.07
The last earnings report on March 28 showed earnings per share of -5 cents, meeting the estimate of -5 cents. With 14.22K shares outstanding, the current market capitalization sits at 76.31M.